Table 2.

Use of concomitant medications for SHPT at baseline and during the assessment phase in the efficacy populationa

Baseline(n = 53)Assessment Phase(n = 53)
Active vitamin D derivative use
    received active vitamin D derivative (n [%])53 (100)42 (79)
    paricalcitol dose equivalentsb (μg/wk [mean ± SD])14.1 ± 7.8\f6.9 ± 4.6c
Phosphate binder use53 (100)52 (98)
Sevelamer use
    received sevelamer (n [%])31 (59)30 (57)
    sevelamer dose (mg/d [mean ± SD])9036 ± 50338250 ± 4980d
Ca-based phosphate binder use
    received a Ca-based phosphate binder (n [%])33 (62)42 (79)
    total elemental Ca intake (mg/d [mean ± SD])1435 ± 10301847 ± 1307e
  • a SHPT, secondary hyperparathyroidism.

  • b 2 μg paricalcitol = 1 μg doxercalciferol = 0.5 μg calcitriol.

  • c P < 0.0001 among 42 patients on active vitamin D derivatives at baseline and in assessment phase.

  • d P = 0.13 among 28 patients who were on sevelamer at baseline and in assessment phase.

  • e P = 0.0013 among 32 patients on Ca-based phosphate binder at baseline and in assessment phase.\